Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of YZJ-1139 in Healthy Participants

NCT06673927 is registered in ClinicalTrials.gov with Shanghai Haiyan Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06673927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06673927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of YZJ-1139 in Healthy Participants
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 1, 2017
Completion date
March 8, 2019
Enrollment
104 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia